Hussien Hishmat: There Is More to Pulmonary Embolism than Just Anticoagulation

Hussien Hishmat, Professor ot Cardiology and Interventional Cardiologist at Tadawi Healthcare, shared on LinkedIn:

”There is more to Pulmonary embolism than just anticoagulation!

• How to manage RV failure?
• When to deploy ECMO?
• How can thrombectomy help?
• Who should get an IVC filter?
• Is screening for cancer useful?

Today, we reach the advanced stage of our Pulmonary Embolism (PE) series, aligning with the latest ACC/AHA guidelines.

Let’s jump into advanced, high-stakes ICU and difficult clinical decisions.

1. Hemodynamic Management of Acute RV Failure

An acute PE spikes Pulmonary Vascular Resistance (PVR), dilating the thin-walled right ventricle (RV) and causing ischemia.

When RV diastolic pressure matches systemic pressure, RV coronary perfusion stops, triggering sudden collapse.

• Cautious Fluids: If the patient isn’t volume-depleted, give a limited 200–500 mL challenge. Excessive fluids over-distend the RV, worsen tricuspid regurgitation, and cause a leftward septal shift that drops systemic perfusion.
• Norepinephrine: First-line vasopressor that raises SVR and restores RV coronary perfusion. Keep the dose <15 mcg/min to prevent PVR elevation.
• Dobutamine: Add if extra support is needed. Its beta-1 inotropic effect pairs perfectly with background norepinephrine. Avoid Milrinone due to its long half-life and hypotensive risks.
• Inhaled Nitric Oxide (iNO): Selectively lowers PVR without systemic vasodilation. Use for Stages C2 to E2.

2. Mechanical Solutions: ECMO and Thrombectomy

• VA-ECMO: A vital rescue bridge for Stages E1 and E2. It unloads the RV, restores coronary perfusion, and bypasses hypoxic lungs. Note: Hemorrhage is more common than circuit thrombosis due to large lines and heparinization.
• Percutaneous Mechanical Thrombectomy: Class IIa recommendation for refractory shock. Large-bore aspiration decompresses the RV safely but carries access-site bleeding risks. Avoid in stable patients.
• Surgical Embolectomy: Reserved for Stage E1 shock. Provides instant RV decompression with a near-zero risk of intracranial hemorrhage.

3. The Realities of IVC Filters

Filters cut short-term recurrent PE by 50% but offer zero all-cause mortality benefit. Long-term placement carries a 70% late DVT risk plus perforation hazards.

• Absolute Indications: Absolute contraindication to anticoagulation or objective treatment failure.
• Retrieval Window: Filters must be pulled between Day 29 and Day 54 before embedding into the IVC wall.

4. PERT and Targeted Screenings

• PERT Teams: Class I recommendation for Stages C, D, and E to coordinate multidisciplinary care and shorten time to therapeutic anticoagulation.
• Thrombophilia: Only screen unprovoked PE patients under age 55 or with a strong family history. Draw functional assays only after the acute phase resolves.
• Cancer: 4%–10% of unprovoked PEs are diagnosed with cancer within a year. Avoid routine pan-CT/PET screening (high false positives, no survival benefit). Rely on history, physicals, and standard age-guided screenings.

5. Chronic Sequelae: CTEPD and CTEPH

Evaluate patients with persistent dyspnea beyond 3 months of anticoagulation for Chronic Thromboembolic Pulmonary Disease (CTEPD) or Pulmonary Hypertension (CTEPH).

• 4-Test Panel: Get an Echo (screening), a V/Q scan (gold standard screen), a CTPA (anatomy), and a CPET (functional assessment).
• Treatment: Refer to a high-volume center for lifelong anticoagulation, Riociguat, or definitive procedures: Surgical Pulmonary Endarterectomy (PEA) for proximal clots, or Percutaneous Balloon Pulmonary Angioplasty (BPA) for distal disease.

How have these updated guidelines shifted your practice?

Let’s discuss in the comments below!”

Stay updated with Hemostasis Today.